CD8A and neoplasm: Additionally, it was also observed that A2AR antagonist could rescue tumor-reactive T cells (mainly CD8+ T cells) by reducing cAMP levels, freeing anti-tumor T cells from adenosine-mediated suppression, and enhancing the production of pro-inflammatory cytokines 166.